By Dean Seal


Galectin Therapeutics Inc. filed an investigational new drug application with regulators for its drug Belapectin in combination with a checkpoint inhibitor as a treatment for head and neck cancer.

The biotechnology company said Wednesday that the application was filed with the U.S. Food and Drug Administration's oncology division, and that it has received the agency's approval to proceed with a Phase 2 trial for Belapectin. The trial will evaluate Belapectin in combination with Keytruda as a first-line treatment for head and neck cancer patients.

Shares were up 6% to $1.72 in premarket trading.


Write to Dean Seal at dean.seal@wsj.com


(END) Dow Jones Newswires

10-12-22 0849ET